Covaxin phase 3 data reveals 77.8% efficacy, know how it fares against Covishield

Covaxin shows 77.8 % efficacy in phase 3 trial data in review by subject expert committee (SEC), according to Sources.

The data has been revealed today only and if it is able to fullfill WHO norm, the vaccine will be granted permission for international usage.

While Covaxin vs Covishield debate goes on in the country, the data might put an end to it as both vaccines exhibit almost similar efficacy.

However, efficacy of Covieshield depends largely on the gap period between two doses.